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There is urgent need for biomarkers that provide early detection of pancreatic ductal adenocarcinoma (PDAC) as well as
discrimination of autoimmune pancreatitis, as current clinical approaches are not suitably accurate for precise diagnosis. We
used mass spectrometry to analyze protein proﬁles of more than 300 plasma specimens obtained from PDAC, noncancerous
pancreaticdiseasesincludingautoimmunepancreatitispatientsandhealthysubjects.Weobtained1063proteomicsignalsfrom160
plasma samples in the training cohort. A proteomic signature consisting of 7 mass spectrometry signals was used for construction
of a proteomic model for detection of PDAC patients. Using the test cohort, we conﬁrmed that this proteomic model had
discrimination power equal to that observed with the training cohort. The overall sensitivity and speciﬁcity for detection of cancer
patients were 82.6% and 90.9%, respectively. Notably, 62.5% of the stage I and II cases were detected by our proteomic model.
We also found that 100% of autoimmune pancreatitis patients were correctly assigned as noncancerous individuals. In the present
paper, we developed a proteomic model that was shown able to detect early-stage PDAC patients. In addition, our model appeared
capable of discriminating patients with autoimmune pancreatitis from those with PDAC.
1.Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the ﬁfth lead-
ing cause of cancer death in Japan with more than 24,000
deaths annually [1], while 35,000 deaths each year in the
United States are caused by the disease [2]. Long-term
survival for PDAC patients remains unsatisfactory, with only
3–5%survivingformorethan5yearsaftersurgicalresection,
with the remainder succumbing to widespread metastasis
or massive local recurrence. Since surgical resection is the
only reliable curative treatment, early detection is essential
to improve the outcomes of aﬀected individuals. However,
the clinical symptoms of PDAC are often unremarkable
until advanced stages of the disease, and the anatomic2 International Journal of Proteomics
location of the pancreas deep in the abdomen makes physical
detection and imaging approaches diﬃcult. Thus, less than
10%ofpatientsdiagnosedwithPDACareeligibleforsurgical
resection [3]. Although serum markers for PDAC including
carcinoembryonic antigen (CEA) and carbohydrate antigen
19-9 (CA19-9) play important roles in current clinical
practice for monitoring progression and treatment response,
as well as surveillance for recurrence, these markers are not
ideal for cancer screening due to their low speciﬁcity and/or
sensitivity in early stages of the disease [4–6].
The concept of autoimmune pancreatitis (AIP) is sup-
ported by recent advances in elucidating its pathogenesis
as a unique systemic disease. AIP has several characteristic
features, such as inﬁltration of CD4-positive T cells and
IgG4-positive plasmacytes, irregular narrowing of the pan-
creatic duct, and diﬀuse enlargement of the pancreas [7–9].
Although intensive investigations into the pathogenesis of
AIP have been conducted, its underlying molecular mecha-
nism remains unclear. The most important and diﬃcult step
in diagnosing AIP is to distinguish it from PDAC. Clinical
symptoms such as obstructive jaundice are not helpful for
discrimination, while IgG4, the most accurate serum marker
for AIP, is not adequately speciﬁc to exclude the existence
of cancer. Furthermore, AIP is sometimes accompanied by
PDAC; thus percutaneous or endoscopic biopsy ﬁndings
are often needed for ﬁnal diagnosis. Unfortunately, those
examinations are invasive for the patient and may fail to
detect small regions of cancer cells. As a result, unnecessary
surgery because of misdiagnosis performed for AIP patients
without cancer or those undergoing treatment for existing
cancerisacriticalissueinclinicalpractice.Accordingly,there
is urgent need for elucidation of novel biomarker(s) and
noninvasive diagnostic strategies useful for early detection
of PDAC, as well as discrimination of patients with AIP to
improve clinical management and prognosis.
Comprehensive analysis of protein expression patterns
in biological materials might improve understanding of the
molecular complexities of human diseases [10]a n dc o u l db e
useful to detect diagnostic or predictive protein expression
patterns that reﬂect clinical features. Matrix-assisted laser
desorption/ionization mass spectrometry (MALDI MS) can
proﬁle proteins up to 50kDa in size in serum, tissues, and
other various clinical specimens. Protein proﬁles obtained
maycontainthousandsofdatapointsandprovideproteomic
signatures that allow detection of patients with various
diseases [11, 12]. We previously employed MALDI MS
for expression proﬁling of proteins in human lung cancer
specimens and found that the resultant proteomic patterns
could predict various clinical features, as well as the potential
of recurrence in stage I lung cancer patients [13, 14].
In the present study, protein expression proﬁling with
MALDI MS was conducted to identify proteomic patterns
in plasma samples for discrimination of PDAC from AIP
as well as chronic pancreatitis (CP) using 3 independent
datasets. We found that a proteomic model consisting of 7
mass spectrometry signals constructed by use of the training
cohort could detect 82.6% (38 of 46, 95% CI 68.6–92.2) of
known PDAC cases, including 62.5% (5 of 8, 95% CI 24.5–
91.5)ofthestageIandIIcasesintheindependenttestcohort,
which successfully conﬁrmed its discrimination power. We
further applied our model for discrimination of AIP as well
as CP from PDAC and found that it correctly assigned 100%
of the AIP and CP patients (19 of 19, 95% CI 82.4–100
and 11 of 11, 95% CI 71.5–100, resp.) as noncancerous.
Theseresultsindicatethatour7-signalproteomicmodelmay
contribute to accurate decisions regarding the therapeutic
plan for patients with chronic pancreatic diseases, especially
PDAC and AIP.
2. Methods
2.1. Patients and Specimens. Plasma specimens from 96
PDAC patients were obtained from the Department of Epid-
emiology and Prevention, Aichi Cancer Center Research
Institute, Nagoya, Japan, collected from January 2001 and
November 2005. Of those, 80 were randomly assigned to
the training set and 16 to the test set. An additional 30
plasma specimens from PDAC patients were obtained from
the Department of Surgery, Nagoya University Hospital,
Nagoya, Japan, collected from May 2004 to July 2006, and
assigned to the test set. Plasma specimens from 147 healthy
control subjects were also obtained from the Department of
Epidemiology and Prevention, Aichi Cancer Center Research
Institute, and used. Of those, 80 were randomly assigned
to the training set and 67 to the test set. Plasma specimens
from 2 acute pancreatitis, 11 chronic pancreatitis, and
3 autoimmune pancreatitis patients were obtained from
the Department of Gastroenterology, Nagoya University
Hospital, collectedfromApril 2005 andNovember 2007, and
assigned to the test set. In addition, 16 plasma specimens
from autoimmune pancreatitis were obtained from the
Department of Gastroenterology, Nagoya University Hospi-
tal, collected from September 2003 and August 2009, and
assigned to the conﬁrmation set. More detailed information
is available in Supplementary Material available on line at
doi: 10.1155/2012/510397. The characteristics of the patients
and healthy subjects in the training, test, and conﬁrmation
cohorts are summarized in Supplementary Table S1, which
shows that there were no statistically signiﬁcant diﬀerences
in regard to clinicopathologic features among the cohorts.
All specimens were processed in the same manner and stored
at −80◦C within 180 minutes after being collected from the
patients and healthy subjects, and not thawed until analysis.
Requisite approval from our institutional review boards and
written informed consent from all subjects were obtained.
One plasma specimen per patient or healthy subject was
analyzed, and the training, test, and conﬁrmation datasets
were independently analyzed as diﬀerent batches. Further
details are available in supplementary Material.
2.2. Proteomic Analysis. Five microliters of nonpre-treated
plasma was mixed with 5 nL drops of an energy absorbing
matrix solution (saturated Sinapinic acid in water/aceto-
nitrile/triﬂuoroacetic acid (500:500:1, by volume), which
allows molecules to be protonated and desorbed from tissue
surfaces).Then,1µLmixturesweredepositedintoindividual
wells of MALDI MS sample plates (PE Biosystems, FosterInternational Journal of Proteomics 3
City, CA) and dried at room temperature for 5 minutes.
Six spots were generated for each plasma-matrix mixture
sample and spectra were acquired from all 6 using a 4800
Instrument(AppliedBiosystems,FosterCity,CA),essentially
as described previously [13, 14]. Further details are available
in Supplementary Material.
2.3. Statistical Methods. Protein proﬁles obtained by MALDI
MS were analyzed using 3 distinct statistical methods,
Fisher’s exact test, the Kruskal-Wallis test, and a signiﬁcance
analysis of microarray (SAM) test [15], to investigate MS
signals that appeared to diﬀerentiate PDAC patients from
healthy individuals in the training set. MS signals that met
at least 1 of the 3 selection criteria were further analyzed.
To construct a generally applicable proteomic classiﬁer
without speciﬁcally overﬁtting it to the training cohort,
we used a weighted voting algorithm, a well-established
technique for supervised classiﬁcation, in which each weight
value was calculated as the signal-to-noise ratio and a leave-
one-out cross-validation strategy was utilized [16].
It is possible that unintended biased resubstitution or
partial cross-validation can result in underestimation of the
error rate after cross-validation; thus the performance of
any class prediction rule is best assessed by applying the
rule created by use of 1 dataset (the training set) to an
independent dataset (the validation or test set) [17]. In
the present study, the proteomic classiﬁer constructed with
the training dataset of 160 individuals was validated using
a completely independent validation set composed of 145
individuals.
An agglomerative hierarchical clustering algorithm was
applied to investigate the pattern among the statistically
signiﬁcant discriminator proteins as well as the biological
status with Eisen’s software [18].
2.4. Identiﬁcation of Individual Proteins in the Proteomic
Signature. 40µ of serum samples was pretreated with high
abundant protein depletion column (Agilent, Palo Alto,
CA) according to manufacturer’s instruction. The pretreated
serum samples were separated over a polymeric column
(Toso, Tokyo, Japan) with a high-performance liquid chro-
matography (HPLC) pump (Shimadzu, Osaka, Japan) and
HPLC fractions were collected every minute for 80 minutes.
Each fraction was lyophilized, reconstituted with a 50%
acetonitrile in water containing 0.1% triﬂuoroacetic acid,
and analyzed by MALDI mass spectrometry to identify the
HPLC fractions that contained proteins corresponding to
the peaks in the signature with molecular weights selected
by bioinfomatic analysis as candidate molecular markers
for the PDAC. The selected fractions were lyophilized and
reconstituted with a mixture of 10µL of 0.4M ammonium
hydrogen carbonate and 5µL of 45mM dithiothreitol, and
then 10µL of 100mM iodoacetamide was added. This mix-
t u r ew a si n c u b a t e df o r4h o u r sa t3 7 ◦Cw i t h5µL of 200nM
mass-grade trypsin (Promega, Madison, WI) to obtain
peptides. The peptides were separated and sequenced by
a microcapillary reverse-phase column (KYA technologies,
Tokyo, Japan) with an HPLC pump (KYA) and MALDI
mass spectrometer (Applied Biosystems). These spectra were
compared with those in the human databases of the National
Center for Biotechnology Information (nonredundant) by
use of Mascot version 2.1.0 (Matrix Science Inc., Boston,
MA). A minimum of two peptide matches and a positive
association between the m/z values detected with MALDI
mass spectrometry and the molecular weight of the intact
protein (including posttranslational modiﬁcations) were
required for protein identiﬁcation.
3. Results
3.1. Protein Expression Proﬁling in the Training Cohort. We
obtained protein expression proﬁles for the 160 human
plasma specimens obtained from 80 PDAC patients and
80 healthy subjects at Aichi Cancer Center (Figure 1(a))
and Supplementary Table S1) using MALDI MS. Spectra
were obtained from 6 replicates of single plasma specimens.
MarkerView(AppliedBiosystems)andcustomsoftwarewere
used to bin the peaks across the spectra obtained from
960 samples, and then we calculate the average intensity of
each signal individually among the 160 cases. As a result,
we obtained expression proﬁles containing 1063 distinct
proteomic signals. To extract a proteomic signature able to
discriminate PDAC patients from healthy individuals, we
compared MS signals from the 80 healthy subjects and 80
PDAC patients using our statistical selection criteria (signals
met at least 2 of the following criteria: P value corrected
with Bonferroni was less than 0.05 in Fisher’s exact test and
Kruskal-Wallis test, and FDR < 0.1% for SAM). As a result,
134 MS signals were found to be diﬀerentially expressed.
Agglomerative hierarchical clustering analysis using the
identiﬁed proteomic signature showed a clear separation of
plasma specimens from PDAC patients as compared to those
fromhealthyindividuals(Figure 1(b)),whichconﬁrmedthat
the selected MS signals were informative for discrimination
of PDAC cases from healthy individuals. The left branch
mostly consisted of PDAC cases (81.3%, 65 of 80 cases,
95% CI 71.0–89.1), whereas the right branch consisted of
healthy subjects (78.8%, 63 of 80 cases, 95% CI 68.2–87.1).
Next, we investigated whether our proteomic prediction
model could best distinguish noncancerous individuals from
cancer patients. For this purpose, the 134 selected MS
signals, which were informative for discrimination, were
further ranked according to the SAM and weighted-voting
proteomic discriminatory models were constructed using
increasing numbers of the diﬀerentially expressed proteomic
signals (up to 134), for which learning errors were calculated
by leave-one-out cross-validation (Figure 2(a)). This cross-
validation analysis showed that the use of 7 MS signals
gave the lowest number of misclassiﬁcations, while 7 MS
signals(8562.3,8684.4,8765.1,9423.5,13761.5,14145.2,and
17250.8m/z) were extracted as the most shared ones. Using
this proteomic model, plasma samples from both PDAC
patients and healthy subjects were classiﬁed as either positive
or negative for cancer, which showed that the sensitivity for
prediction was 76.3% (61 of 80 of the cancer patients, 95%
CI 65.4–85.1) and for speciﬁcity was 91.3% (73 of 80 of the
healthy subjects, 95% CI 82.8–96.4, Table 1), for an overall4 International Journal of Proteomics
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Figure 1: MALDI MS analysis of plasma specimens from human
PDAC patients and healthy subjects in the training cohort.
(a) Independent training-validation-conﬁrmation datasets of 160
training cases, 129 validation cases, and 16 conﬁrmation cases. (b)
Unsupervised hierarchical clustering analysis of 80 human PDAC
patients and 80 healthy subjects in the training cohort according
to the protein expression patterns of 134 MS signals. Each row
represents an individual proteomic signal and each column an
individualsample.Thedendrogramatthetopshowsthesimilarities
in protein expression proﬁles among the samples. Substantially
elevated (red) expression of the proteins was observed in individual
plasma samples. HS: healthy subjects; PDAC: pancreatic ductal
adenocarcinoma. Red box case: PDAC: blue box case: healthy
subject.
classiﬁcation accuracy of 83.8% (134 of 160, 95% CI 77.1–
89.1). We also calculated positive and negative predictive
values(PPVandNPV,resp.)toconﬁrmthediagnosticpower
of our model, which were 89.8% and 79.3%, respectively.
We observed no signiﬁcant diﬀerence for detection of PDAC
patients related to lymph node positivity and prognosis.
Furthermore, we analyzed the relationship between the age
of PDAC patients (≤60 or >60 years old) and detection
power of the 7 MS signals. Those results showed that the
sensitivity for prediction was 69.8% (30 of 43, 95% CI 53.9–
82.8) and 83.8% (31 of 37, 95% CI 68.0–93.8) in the younger
and older groups, respectively (Table 1), with no signiﬁcance
in discrimination found (P = 0.142, Fisher’s exact test).
Representativespectrathatcomprisedthe7-signalproteomic
model for the healthy subjects and PDAC patients are shown
in Figure 2(b). It is of note that our model was able to
correctlydistinguish 72.7%(8of11cases,95%CI39.0–94.0)
of the stage I and II cases from the healthy subjects, while it
also correctly classiﬁed 78.8% (26 of 33, 95% CI 61.1–91.0)
ofthePDACpatientseligibleforsurgicalresectionaspositive
for cancer (Table 1).
3.2.ProteinExpressionProﬁlingintheTestCohort. Ithasbeen
well reported that the robustness, including accuracy, of a
prediction model should be assessed using an independent
validation cohort, even when cross-validation methods, such
as LOOCV or n-fold CV, were properly used for developing
the prediction model [19]. To examine the robustness of
the 7-signal proteomic model constructed with data from
MALDI-MS analysis of the training cohort, we applied it to
an independent test dataset obtained from plasma samples
collected at two diﬀerent institutions. We also determined
whether the identiﬁed proteomic model could discriminate
between acute and chronic pancreatitis patients, as well as
autoimmune pancreatitis, as the discovery of biomarkers
applicable for diﬀerential diagnosis between PDAC and
noncancerous pancreatic diseases has great potential for
clinical practice. For the test cohort, plasma samples were
obtained from 46 PDAC patients (16 and 30 cases of ACC
and NUH, resp.) and 67 healthy subjects from the ACC
group, while 16 pancreatitis samples obtained from Nagoya
University hospital (NUH) consisted of 2 acute pancreatitis,
11 chronic pancreatitis, and 3autoimmune pancreatitis cases
(Figure 1(a), Supplementary Tables S1 and S2 for additional
clinical information for AIP patients). With the 7-signal
proteomic model, 82.6% (38 of 46, 95% CI 68.6–92.2) of
the cancer cases were classiﬁed into the positive group, while
89.2% (74 of 83, 95% CI 80.4–94.9) of the noncancerous
subjects were assigned to the group negative for cancer
(Figure 3 and Table 2). We calculated PPV and NPV, which
were 80.9% and 90.2%, respectively, and the overall accuracy
of the classiﬁcation with the test cohort was 86.8% (112 of
129, 95% CI 79.7–92.1). We also evaluated the relationship
between blood vessel invasion (surgery with or without
mesenteric venous tract resection) and detection power of
the 7 MS signals. Our results showed that the sensitivity for
prediction was 88.8% (8 of 9, 95% CI 51.8–99.7) for PDAC
patients who underwent mesenteric venous tract resection
and 78.6% (11 of 14, 95% CI 49.2–95.3) for those who did
not, with no signiﬁcant diﬀerence found (P = 0.524, Fisher’s
exact test). Future studies with a larger number of PDAC
patients treated with surgery are warranted to validate the
clinicalusefulnessofour7-signalproteomicsignature.Itisof
note that our model was able to correctly distinguish 62.5%International Journal of Proteomics 5
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Figure 2: Construction of proteomic model for discrimination of PDAC cases from healthy subjects. (a) Schematic diagram of construction
ofproteomicdiscriminationmodel.(b)Representativemassspectracomprising7-signalproteomicsignature.Arrowheadsshowinformative
peaks for discrimination between healthy subjects and PDAC patients. Blue lines show representative spectra from healthy subjects and red
lines show representative spectra from PDAC patients.
Table 1: Discrimination of samples in the training cohort according to 7-signal proteomic model.
Number of cases
analyzed
Number of correctly
assigned cases (%)
95% C.I.∗ (%)
All samples 160 134 (83.8) 77.1–89.1
Pancreatic ductal adenocarcinoma 80 61 (76.3) 65.4–85.1
Healthy subjects 80 73 (91.3) 82.8–96.4
age
≤60 43 30 (69.8) 53.9–82.8
>60 37 31 (83.8) 68.0–93.8
Clinical stage of pancreatic ductal adenocarcinoma patients
0/I 3 3 (100) 29.2–100
II 8 5 (62.5) 24.5–91.5
III 8 8 (100) 63.1–100
IVa 14 10 (71.4) 41.9–91.6
IVb 47 35 (74.5) 59.7–86.1
∗95% conﬁdence interval.6 International Journal of Proteomics
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Figure 3: Assessment of 7-signal proteomic model with the
validation cohort using weighted voting algorithm. The results of
proteomic analyses of the training cohort are shown. Each circle
represents a voting sum for a single patient. Solid circles: specimens
whosepredictionwithproteomicmodelmatchedclinicaldiagnosis;
opencircles:specimenswhosepredictionwithproteomicmodeldid
not match clinical diagnosis; HS: healthy subjects; AP: acute pan-
creatitis; CP: chronic pancreatitis; AIP: autoimmune pancreatitis;
PDAC: pancreatic ductal adenocarcinoma.
(5 of 8 cases, 95% CI 24.5–91.5) of the stage I and II cases
from the healthy subjects and also classiﬁed 78.9% (30 of 38,
95% CI 62.7–90.5) of the PDAC patients eligible for surgical
resection as positive for cancer. It is also noteworthy that
the identiﬁed proteomic model distinguished 100% of the
patients with chronic pancreatitis (11 of 11, 95% CI 71.5–
100) and AIP (3 of 3, 95% CI 29.2−100) from cancer cases
(Figure 3 and Table 2).
3.3. Discrimination of Autoimmune Pancreatitis from PDAC
Using 7-Signal Proteomic Model. Autoimmune pancreatitis
is a systemic inﬂammatory disease of the pancreas and
several diagnostic criteria have been proposed. However,
their usefulness is under debate and accurate diﬀerential
diagnosis remains diﬃcult. Moreover, an important step in
diagnosing AIP is to discriminate it from PDAC. In the
present study, all (3 of 3) of the AIP patients were correctly
discriminated from those with PDAC in the analysis with the
test dataset; thus we next performed a conﬁrmatory analysis
using plasma samples collected from 16 AIP patients treated
at NUH (Figure 1(a) and Supplementary Table S2). For this,
we employed our 7-signal proteomic model to investigate
whether it would classify the AIP patients as noncancerous
andfoundthatitcorrectlyassignedthosepatientsasnegative
for cancer with 100% accuracy (16 of 16 cases, 95% CI 79.4–
100). Therefore, the high potential for discrimination of AIP
fromPDACwasvalidatedwithanindependentconﬁrmatory
dataset used in a blinded manner. The serum level of CA19-9
was elevated in 4 (21.1%, 95% CI 7.3−52.4) of the AIP
cases in our cohort, while IgG4 levels have been reported
to be elevated in 10–30% of PDAC cases [7, 20]. Thus, our
proteomic model may be applicable as a novel serological
test to discriminate AIP from PDAC in clinical practice.
Representative spectra obtained from the AIP and PDAC
cases are shown in Figure 4.
3.4. Combination of MALDI Proteomic Signature and CA19-9
forCancerScreening. Our7-signalproteomicmodelwasable
to detect 82.6% (38 of 46, 95% CI 68.6–92.2) of the PDAC
patients in the test cohort (Table 2). Moreover, it assigned
78.9% (30 of 38, 95% CI 62.7–90.5) of the patients eligible
for an operation to the cancerous group, while 62.5% (5 of
8 and 95% CI 24.5–91.5) of the stage I and II cases were
also detected with the identiﬁed model. Since it is possible
that our 7-signal proteomic model and CA19-9 level are
complementary, we investigated whether their combined use
wouldimprovethedetectionrateofpatientswhomaybeneﬁt
from surgery. The overall sensitivity of CA19-9 (cutoﬀ value,
37 units/mL) alone for stage 0–IVa patients was 71.1%
(27 of 38, 95% CI 54.1–84.6), while a combination of our
7-signal proteomic model and CA19-9 level detected 89.5%
(34 of 38, 95% CI 75.2–97.1) of operable cases. Notably,
for detection of stage I and II PDAC patients, CA19-9
assigned only 50.0% (4 of 8, 95% CI 15.7–84.3) of the
cases to the positive group and no additional discrimination
power of that marker was observed when combined with our
proteomic model. Accordingly, we consider that our 7-signal
proteomic model might be more sensitive for detection
of early stage PDAC patients than CA19-9, which would
improve clinical outcomes following surgical treatment.
3.5. Identiﬁcation of Individual Proteins in the Proteomic
Signature. As an initial step toward elucidating the biologic
mechanism of the association between the proteomic signa-
ture and carcinogenesis, we identiﬁed a couple of proteins
that correspond to the mass spectrometry signals in the
proteomicsignatureobtainedfromserum.Extractsfromtwo
serum samples of healthy individual were fractionated by
reverse phase-HPLC and analyzed by MALDI MS to identify
the HPLC fractions that contained proteins corresponding
to peaks in the proteomic signature. These selected fractions
were subjected to sequence analysis of tryptic peptides by
use of MALDI MS. Accordingly, we identiﬁed the following
proteins as part of the proteomic signature: apolipoprotein
A-I ([M + H]+ = 17,250.8m/z) and C-III ([M + H]+ =
8765.1), and transthyretin ([M + H]+ = 13761.5).
4. Discussion
In the present study, we analyzed the protein expression
proﬁles of plasma specimens obtained from patients with
PDAC, as well as acute and chronic pancreatitis cases, and
autoimmune pancreatitis (AIP) patients with MALDI MS.
Using bioinformatic analysis, we derived 7 MS signals that
allowed us to produce a proteomic model for discrimination
of PDAC from noncancerous individuals. When we used
our proteomic model with both independent test cohort
and conﬁrmation group, 62.5% (5 of 8, 95% CI 24.5–91.5)
of stage 0–II cases were correctly assigned to the cancerous
group, while all AIP patients (19 of 19, 95% CI 82.4–100)International Journal of Proteomics 7
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Figure 4: Representative mass spectra comprising 7-signal proteomic signature in autoimmune pancreatitis patients and PDAC patients.
Arrowheads show informative peaks for discrimination between autoimmune pancreatitis patients and patients with pancreatic cancer. Blue
solid and dotted lines show representative spectra from autoimmune pancreatitis patients, and red solid and dotted lines show representative
spectra from pancreatic cancer patients. AIP: autoimmune pancreatitis; PDAC: pancreatic ductal adenocarcinoma.8 International Journal of Proteomics
Table 2: Discrimination of samples in the test cohort according to 7-signal proteomic model.
Number of cases
analyzed
Number of correctly
assigned cases (%)
95% C.I.∗ (%)
All samples 129 112 (86.8) 79.7–92.1
Healthy subjects 67 60 (89.6) 79.7–95.7
Pancreatic ductal adenocarcinoma (ACCH) 16 13 (81.3) 54.4–96.0
Pancreatic ductal adenocarcinoma (NUH) 30 25 (83.3) 65.3–94.4
Acute pancreatitis (NUH) 20 ( 0 ) 0–84.2
Chronic pancreatitis (NUH) 11 11 (100) 71.5–100
Autoimmune pancreatitis (NUH) 3 3 (100) 29.2–100
Clinical stage of pancreatic ductal adenocarcinoma patients at ACCH
0/I 0N A NA
II 10 ( 0 ) 0–97.5
III 3 3 (100) 29.2–100
IVa 4 2 (50) 6.8–93.2
IVb 8 8 (100) 63.1–100
Clinical stage of pancreatic ductal adenocarcinoma patients at NUH
0/I 10 ( 0 ) 0–97.5
II 6 5 (83.3) 35.9–99.6
III 13 11 (84.6) 54.6–98.1
IVa 10 9 (90) 55.5–99.7
IVb 0N A NA
∗95% conﬁdence interval
NA: not available.
were correctly assigned to the noncancerous group. Dis-
crimination of AIP from cancer is obviously important;
however it is currently problematic in clinical practice.
Althoughpreviousreportshaveshowndiscriminationpower
of proteomic signature between PDAC patients and control
subjects [21–24], to the best of our knowledge, the present
7-signal proteomic model is the ﬁrst system of proteomic
prediction based upon mass spectrometry found capable to
both detect early-stage PDAC cases and discriminate AIP
patients.
Earlydetectionisessentialforimprovingtheoutcomesof
PDAC patients. However, those in stages 0–II are diﬃcult to
detect with current diagnostic approaches, including com-
puterized tomography scanning, positron emission tomog-
raphy scanning, and tissue-based diagnostic tests. CA19-9 is
a tumor marker widely used for evaluations of therapeutic
eﬀects and detection of PDAC recurrence, though it is not
considered to be applicable for mass screening when used
alone [4, 6, 25, 26]. Recent advances in molecular biology
have also revealed that clinical features cannot be adequately
characterizedorpredictedbyasinglemarker.Thus,microar-
ray analysis has been employed to simultaneously investigate
the expression levels of thousands of genes and identify
mRNA patterns associated with various human diseases
including PDAC [27–29]. However, mRNA expression does
not always indicate which of the corresponding proteins
are expressed or provide information regarding their post-
translational regulation. Moreover, blood and body ﬂuids,
such as pancreatic juice and urine, do not contain mRNA.
Thus, proteome analysis of such specimens is considered to
better reﬂect the underlying clinical characteristics of human
diseases as compared to gene expression proﬁling, while
proteomic technologies including MS have been employed
to analyze proteomes in clinical specimens [10–14, 30–32].
Previous proteomics studies of PDAC with healthy controls
have shown promising results in distinguishing PDAC, with
a sensitivity ranging from 78 to 91% and speciﬁcity from
75 to 100% [21–24, 33, 34]. These discrimination power
results are better than those obtained with the current
CA19-9 marker, while improved diagnostic performance has
been observed when serum MS markers were combined
with CA19-9 [21, 22, 24]. In the present study, we found
that the combination of our 7-signal proteomic model and
CA19-9levelimprovedthepositiverateofdetectionofPDAC
patients eligible for surgical resection to 89.5% (34 of 38,
95% CI 75.2–97.1). It is noteworthy that detection of stage
I-II cases was also attainable at a sensitivity of 62.5% (5 of
8, 95% CI 24.591.5) without further improvement by adding
CA19-9. These results support the usefulness of our 7-signal
proteomic model for detection of early stage cases. Since we
constructed the present 7-signal model independent from
CA19-9, further optimization of selection of a proteomic
signature with focus on early detection possibly along with
adjustment of the CA19-9 cutoﬀ value is warranted to obtain
increased sensitivity. The present 7-signal proteomic model
showed high potential to assign inﬂammatory pancreatic
disease patients to the noncancerous group (93.8%; 30 of
32, 95% CI 79.2–99.2). Interestingly, 2 of the misclassiﬁedInternational Journal of Proteomics 9
patients suﬀered from acute pancreatitis; however, all of the
patients of chronic pancreatitis and AIP (11 of 11, 95% CI
71.5−100; and 19 of 19, 95% CI 82.4–100) were correctly
assigned to the noncancerous group by our proteomic
model. Discrimination of AIP from PDAC is diﬃcult in
clinical practice, as symptoms such as obstructive jaundice
or space occupying lesions in the pancreas are commonly
observed in both cases. Actually, most of the AIP patients
in this study showed at least one of these symptoms. Our
proteomic model distinguished between AIP patients and
those with PDAC with high accuracy; thus it is considered
to be eﬀective in future clinical applications, especially
for selecting those who are eligible for invasive diagnostic
proceduresfollowedbyinevitablyinvasivesurgicaltreatment
for PDAC. During the course of our study, Frulloni et al.
reported that autoantigens against the plasminogen binding
proteinofhelicobacterpyloriandubiquitin-proteinligaseE3
component n-recognin 2 were detected in most of the AIP
patientstested,aswellasasmallnumberofPDACcases[35].
It would be interesting to combine our proteomic model
with testing for those autoantigens for diagnosis of chronic
pancreatic diseases.
In this study, 2 acute pancreatitis patients and 14 healthy
subjectswereassignedtothecancerousgroupbyour7-signal
proteomic model in the training (7 healthy subjects) and test
(2 acute pancreatitis patients and 7 healthy subjects) cohorts.
Since that time, we have carefully followed their clinical
courses of these healthy subjects and found that 5 suﬀered
from cancerous disease within 3 years, including 2 with
rectal cancer, 1 with prostate cancer, 1 with hepatocellular
carcinoma, and 1 with a metastatic bone tumor from an
unknown primary site. In addition, another false positive
healthy subject later developed polyposis in the colon. These
observations suggest potential relation of our proteomic
model with these malignancies, although further in-depth
investigations are apparently required to draw deﬁnitive
conclusions.
Mass spectrometry proﬁles obtained from complex pro-
tein mixtures can contain thousands of data points derived
from real protein signatures. However, they can also be
contaminated by electronic and chemical noise, variability in
instrumentation, and variable crystallization of the matrix,
necessitating careful analytical techniques [11, 13, 14]. In
the present study, we employed multiple statistical methods
and leave-one-out cross-validation to combine diﬀerentially
expressed proteins with the clinical variables and found
that a minimal set of 7 low-molecular weight proteins
was suﬃcient to distinguish between healthy subjects and
PDAC patients. The discriminating power of the extracted
proteomicsignaturewasfurthervalidatedusingindependent
test datasets obtained from plasma specimens collected at
2d i ﬀerent institutions. With this protocol, we carefully
eliminated accidental identiﬁcation of overly optimistic and
nonbiological/mathematical multivariate signatures within a
closed cohort by overﬁtting.
T h ep r i m a r yg o a lo ft h i ss t u d yw a sd e v e l o p m e n to f
a bioassay applicable to clinical practice for detection of
PDAC and discrimination from AIP, as attempts to identify
proteins that comprise a proteomic model have not been
fully successful to date. However, the high reproducibility of
MALDI MS indicates that direct application of its ﬁndings
would be successful. In the previous study, Koomen et al.
reported that a set of 4 peaks could be used to detect
PDAC, of which one MS signal was downregulated in PDAC
patients and found to be derived from apolipoprotein A-
I[ 23], while Yan et al. found that transthyretin levels
were independently associated with PDAC likelihood when
obstructive jaundice was considered [36]. Accordingly, our
identiﬁcation of apolipoprotein A-I and transthyretin, which
is a constituent of our proteomic model and downregulated
in PDAC patients in this study, is in accord with previous
reports from diﬀerent institutes. We also identiﬁed the
downregulation of apolipoprotein C-III in serum samples
obtained from PDAC patients [37, 38]. Further investiga-
tions are warranted to identify discriminating proteins for
ascertainment of their functional signiﬁcance. Notably, 2
downregulated peaks (8765 and 13762m/z), which were
previously extracted as proteomic serum markers for lung
cancer [39], were also identiﬁed as downregulated proteomic
signals in PDAC patients in the present study.
Prospective multi-institutional studies with a larger
number of patients including those with early-stage PDAC,
AIP, and other pancreatic diseases are apparently warranted
to validate further signiﬁcance of our 7-signal proteomic
signature for clinical application. Given that it has potential
for early detection of PDAC as well as accurate discrimina-
tion of AIP, our 7-signal proteomic model may ultimately
lead to a reduction in the large number of deaths caused by
devastating cancer and also provide better management for
chronic inﬂammatory disease of pancreas.
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